These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30214892)

  • 1. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.
    Beck KM; Sanchez IM; Yang EJ; Liao W
    Psoriasis (Auckl); 2018; 8():49-58. PubMed ID: 30214892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
    Mui UN; Patel RR; Vangipuram R; Tyring SK
    Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.
    Näslund-Koch C; Zachariae C; Skov L
    Ther Clin Risk Manag; 2020; 16():903-916. PubMed ID: 33061395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tildrakizumab for the treatment of psoriasis.
    Bangert C; Kopp T
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
    Armstrong AW; Read C
    JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
    Crowley JJ; Warren RB; Cather JC
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A; Ulschmid C; Gordon KB
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations.
    Galluzzo M; Chiricozzi A; Cinotti E; Brunasso G; Congedo M; Esposito M; Franchi C; Malara G; Narcisi A; Piaserico S; Tiberio R; Argenziano G; Fabbrocini G; Parodi A
    Expert Opin Biol Ther; 2022 Mar; 22(3):367-376. PubMed ID: 34607513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for the primary care physician: Review and treatment of psoriasis.
    Schadler ED; Ortel B; Mehlis SL
    Dis Mon; 2019 Mar; 65(3):51-90. PubMed ID: 30037762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-23 in psoriasis: current perspectives.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    Psoriasis (Auckl); 2018; 8():1-5. PubMed ID: 29441315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.
    Pithadia DJ; Reynolds KA; Lee EB; Liao W; Wu JJ
    Ther Adv Chronic Dis; 2019; 10():2040622319865658. PubMed ID: 31448070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge.
    Ruggiero A; Camela E; Potestio L; Fabbrocini G; Megna M
    Expert Opin Drug Saf; 2022 Dec; 21(12):1445-1451. PubMed ID: 36527300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.
    Campa M; Mansouri B; Warren R; Menter A
    Dermatol Ther (Heidelb); 2016 Mar; 6(1):1-12. PubMed ID: 26714681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.